Role of Regulatory B Cells in Behçet's Disease

Study Overview
=================
Brief Summary
-----------------
There are limited data about the role of regulatory B cells in Behcet Disease. In this study we aimed to identify the proportions of total B lymphocytes and their regulatory subset in different Behcet Disease phenotype and therapies concentrating on the cardiovascular system attempting to unravel their function in Behcet Disease.

Detailed Description
-----------------
Behçet's disease is a chronic multi-organ vasculitis characterized by recurrent oral and genital aphthae, skin lesions, widespread thrombosis and aneurysmal formation, and serious involvement of the eyes and central nervous system. The innate and adaptive immune cells integrate in the pathogenesis of Behçet's disease. Interestingly, the gene expression analysis of Behçet's disease patients and healthy controls revealed the modulation of a range of genes involved in biological processes in Behçet's disease such as inflammation, apoptosis, angiogenesis, blood coagulation, vascular damage, signalling pathways, and immune responses, particularly, in innate immune cells, Th17 cells and B cells. Yet, the regulatory role of B cells in Behçet's disease has not been thoroughly investigated. Therefore, the aim of the current study is to identify the proportions of total B lymphocytes and their regulatory subset in different Behçet's disease phenotypes and therapies attempting to unravel their function in Behcet Disease. The role of B cells and regulatory B cells in the cardiovascular system affection in Behcet Disease was studied in more details.

Official Title
-----------------
Possible Role of Regulatory B Cells in Behçet's Disease: Special Interest in Cardiovascular System

Conditions
-----------------
Behcet Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Flow-cytometric assay
* Diagnostic Test: 2D Echocardiographic analysis
* Diagnostic Test: Two-Dimensional speckle tracking echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thirty five adult patients who fulfilled the diagnostic criteria of Behcet Disease, and 39 age and sex matched healthy subjects as control Exclusion Criteria: Patients younger than 18 years old and those who were affected by other rheumatic disease other than Behcet Disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with Behcet disease<br>Flow-cytometric assay Detailed 2 Di mention Echocardiographic analysis Two-Dimensional speckle tracking echocardiography | Diagnostic Test: Flow-cytometric assay<br>* 100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.<br>Diagnostic Test: 2D Echocardiographic analysis<br>* Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer<br>Diagnostic Test: Two-Dimensional speckle tracking echocardiography<br>* Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.<br>|
| Healthy control subjects<br>Flow-cytometric assay | Diagnostic Test: Flow-cytometric assay<br>* 100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of B and B regulatory cells in different Behcet phenotype | correlation between the B and B regulatory cells with different presentations of Behcet disease especially the cardiovascular manifestations. | 1 day (done once) |